FAM160B2

Across TCGA pan-cancer cohorts, FAM160B2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FAM160B2 data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FAM160B2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FAM160B2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, UCEC, and LUAD are the cancer types where FAM160B2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.850	0.591	.001	43	view →
UCEC	DFS	Tertile	II,III,IV	1.000	0.489	.013	24	view →
LUAD	DFS	Median	III,IV	0.247	0.805	.001	15	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FAM160B2–HNSC (OS)

Open the HNSC breakdown →